Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.65 |
| ▸ | PPARG | P37231 | 7/20 | 0.65 |
| ▸ | PPARA | Q07869 | 6/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL7805176 | 0.99 | FFAR1 (0.64) | FFAR1PPARGPPARA | |
| Water SCHEMBL7805181 | 0.99 | FFAR1 (0.64) | FFAR1PPARGPPARA | |
| SCHEMBL1299855 | 0.81 | FFAR1 (0.80) | FFAR1PPARGPPARA | |
| SCHEMBL7812508 | 0.80 | FFAR1 (0.41) | FFAR1PPARGPPARA | |
| SCHEMBL8316232 | 0.80 | FFAR1 (0.84) | FFAR1PPARGPPARA | |
| SCHEMBL1746645 | 0.78 | FFAR1 (1.00) | FFAR1PPARGPPARA | |
| SCHEMBL1747426 | 0.77 | FFAR1 (0.78) | FFAR1PPARGPPARA | |
| SCHEMBL8312136 | 0.76 | FFAR1 (0.87) | FFAR1PPARGPPARA | |
| Thiazolidinedione SCHEMBL8475028 | 0.76 | MAOA (0.42) | FFAR1PPARGPPARA | |
| SCHEMBL8809683 | 0.76 | FFAR1 (0.57) | FFAR1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0919232-B1 | Composition for use in the treatment and prevention of hyperuricemia | SANKYO CO (JP) | 2004-10-06 | — | — | EP | claimed |
| US-6569877-B2 | Benzimidazolyl phenyl anticancer agents | SANKYO COMPANY, LIMITED (JP) | 2003-05-27 | — | — | US | claimed |
| US-20020137776-A1 | Therapeutic and prophylactic agents for neoplasms | SANKYO COMPANY, LIMITED (JP) | 2002-09-26 | — | — | US | claimed |
| EP-1197211-A1 | PREVENTIVE AND THERAPEUTIC AGENTS FOR CANCER | Sankyo Company, Limited (JP) | 2002-04-17 | — | — | EP | claimed |
| US-6353009-B1 | TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-03-05 | — | — | US | claimed |
| EP-0745600-B1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | claimed |
| EP-0919232-A1 | Composition for use in the treatment and prevention of hyperuricemia | Sankyo Company Limited (JP) | 1999-06-02 | — | — | EP | claimed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | claimed |
| EP-0919232-B1 | Composition for use in the treatment and prevention of hyperuricemia | SANKYO CO (JP) | 2004-10-06 | — | — | EP | disclosed |
| EP-1197211-A1 | PREVENTIVE AND THERAPEUTIC AGENTS FOR CANCER | Sankyo Company, Limited (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-6353009-B1 | TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-03-05 | — | — | US | disclosed |
| EP-0745600-B1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6150371-A | WITH THE EXCEPTION OF TYPE I DIABETES; INHIBITS INVASION OF ORGAN TISSUE BY CYTOTOXIC LYMPHOCYTES; ADMINISTERING TO A MAMMAL AN ANTIAUTOIMMUNE DISEASE AGENT BEING AN INSULIN RESISTANCE REDUCING AGENT, ANTIDIABETIC, E.G., TROGLITAZONE | SANKYO COMPANY, LIMITED (JP) | 2000-11-21 | — | — | US | disclosed |
| EP-0953355-A1 | REMEDY FOR AUTOIMMUNE DISEASES | Sankyo Company, Limited (JP) | 1999-11-03 | — | — | EP | disclosed |
| EP-0919232-A1 | Composition for use in the treatment and prevention of hyperuricemia | Sankyo Company Limited (JP) | 1999-06-02 | — | — | EP | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137776-A1 | Therapeutic and prophylactic agents for neoplasms | VHL, TP53, BRCA1 | FFAR1 4874/4885PPARG 1300/4885PPARA 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.